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Purpose/Objectives: The purpose of this study is to describe a novel brachytherapy technique for lip Squamous
Cell Carcinoma, utilizing a customized mold with embedded brachytherapy sleeves, which separates the lip from
the mandible, and improves dose homogeneity.
Materials and methods: Seven patients with T2 lip cancer treated with a “sandwich” technique of High Dose Rate
(HDR) brachytherapy to the lip, consisting of interstitial catheters and a customized mold with embedded catheters,
were reviewed for dosimetry and outcome using 3D planning. Dosimetric comparison was made between the
“sandwich” technique to “classic” – interstitial catheters only plan. We compared dose volume histograms for
Clinical Tumor Volume (CTV), normal tissue “hot spots” and mandible dose. We are reporting according to the ICRU
58 and calculated the Conformal Index (COIN) to show the advantage of our technique.
Results: The seven patients (ages 36–81 years, male) had median follow-up of 47 months. Four patients received
Brachytherapy and External Beam Radiation Therapy, 3 patients received brachytherapy alone. All achieved local
control, with excellent esthetic and functional results. All patients are disease free.
The Customized Mold Sandwich technique (CMS) reduced the high dose region receiving 150% (V150) by an
average of 20% (range 1–47%), The low dose region (les then 90% of the prescribed dose) improved by 73% in
average by using the CMS technique. The COIN value for the CMS was in average 0.92 as opposed to 0.88 for the
interstitial catheter only. All differences (excluding the low dose region) were statistically significant.
Conclusion: The CMS technique significantly reduces the high dose volume and increases treatment homogeneity.
This may reduce the potential toxicity to the lip and adjacent mandible, and results in excellent tumor control,
cosmetic and functionality.
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Lip and oral cavity cancer is the 15th most common
cancer worldwide, and the 15th most common cancer in
Europe with more than 300,000 and around 61,400 new
cases diagnosed in 2012 respectively (in both cases 2% of
the total) [1]. The incidence in Europe of oral cavity and
pharynx cancer in 2012 was 99.6 per 100,000 [2]. In* Correspondence: amichaym@gmail.com
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sunshine, the most common sub-site for cancer of the
oral cavity is the lip [3]. The most frequent histologic
type of lip cancer is Squamous Cell Carcinoma. This is
due to the increased exposure to UV radiation in fair-
skinned individuals living in regions exposed to sun.
Due to its location, lip cancer is usually detected at an
early stage and single-modality therapy will usually suf-
fice. Surgery or radiotherapy can be utilized, with similar
local control and overall survival results [4-6].
The extent of surgical resection depends on tumor
size, for small, superficial tumors (less than 5 mm), aal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cient. Larger lesions may however require wide resec-
tions with lip reconstruction, necessitating the use of
flaps [7]. Consequently cosmetic issues may result and
more importantly disruption of the oral sphincter (orbi-
cularis oris muscle), may lead to oral incompetence and
in some cases to microstomia.
Radiation therapy, utilizing external beam and/or brachy-
therapy techniques, is an excellent alternative treatment
option. In terms of disease control, results are similar to
those of surgery [8]. However, in contrast to resection,
functional and cosmetic outcomes are outstanding, and
there are no significant additional toxicities [8-10].
Brachytherapy is a veteran technique and has been in
clinical use for the past 100 years. The major advantage
of brachytherapy is delivery of a high localized dose to
the tumor, with a rapid dose fall-off in the adjacent nor-
mal tissues. In this manner, a high dose is delivered to
the target with relative sparing of the surrounding
healthy tissues. Another important advantage of brachy-
therapy is its short overall treatment time [8].
Various types of applicators and placement techniques
have been used, including hypodermic needles, guide
needles [11], plastic tubes, and guide gutters. Most com-
monly, the rigid or guide needle technique is used for
lower lip cancers [11,12]. Since no randomized trials
have been performed comparing the different modalities,
it is not known if one technique is superior to the other.
Most of the published experience to date comes from
Low Dose Rate (LDR) brachytherapy. An overview of
the literature shows for LDR Iridium-192 brachytherapy
local control rates of 90–95% at 5 years [10]. Limited
published data exists regarding High Dose Rate (HDR)
treatment for lip cancer, However when comparing low
dose rate (LDR) with HDR the long-term results were
equally effective in local control and disease-free sur-
vival, but results with fewer complications when using
HDR [11]. The scarcity of large trials with long-term re-
sults makes it difficult to determine the optimal dose
and fractionation schedule.
Two trails of HDR brachytherapy for lip cancer ap-
peared on a total of 67 patients, reporting 88-96% local
control in 5 years, with excellent functional and cos-
metic results [11,13]. Guinot et al. treated 99 patients
with lip carcinoma with LDR and 104 with HDR brachy-
therapy. Local control at median follow-up above 5 years
in both techniques revealed local contol of 94.9% and
95.2% respectively [11].
Finestres et al. treated 28 patients with HDR bra-
chytherapy applied by superficial ready-made molds,
without invasive needles. They reported 95% control at
46 month follow up [13]. Both studies present results
similar to those obtained with LDR brachytherapy or
surgery.In 2009, The Head and Neck Working Group of
the European Brachytherapy Group (GEC-ESTRO) pub-
lished updated consensus recommendations. These re-
commendations are based mainly on the experience and
publications of its members. In these guidelines, the
rigid needle technique with a template is recommended
for HDR brachytherapy, as it offers the best geometric
conditions for the implant [8].
A recent report published in the Journal of Radiation
Oncology describes the outcome of 51 patients treated
with radioactive gold grain implantation for SCC of the
lip. Most patients included in the trial had T1 lesions.
Results at two-years of follow-up were excellent, both in
terms of local recurrence and cosmetics [14].
The purpose of this work is to describe a novel tech-
nique used at our institution for brachytherapy of lip
cancer and to illustrate its dosimetric advantage over the




The study is a retrospective review of records of patients
treated between 2005–2010 at the Hadassah University
Hospital, Jerusalem, Israel. The study was approved by
Institutional Ethic Committee (number 0125-11-HMO
valid up to 4th of June 2015). A Written informed con-
sent was obtained from the patient whose pictures are
presented in this publication.
Seven patients with a confirmed pathological diagnosis
of squamous cell carcinoma, who were treated for lip
cancer, using either a combination of external beam
radiation therapy and HDR brachytherapy, or HDR
brachytherapy alone, were included.
The brachytherapy technique
A technique using a combination of interstitial sleeve
catheters and a surface mold with embedded sleeve
catheters was employed. One to four flexible plastic
interstitial catheters were implanted to the lip region, in
a single-plane, with 1cm between the catheters. A cus-
tomized acrylic mold was built to separate the lip from
the adjacent bone (mandible or maxilla for lower or
upper lip, respectively). When External Beam Radiation
Therapy (EBRT) was given, this mold served to gain bet-
ter normal tissue protection. The mold was used as a
base for a saddle-shaped extension with embedded ca-
theters and was placed over the patient’s lip (Figure 1).
Brachytherapy was delivered by 192- Iridium based
Nucletron HDR afterloader, (Elekta AB, Stockholm,
Sweden). CT simulation was used for 3D forward plan-
ning by Plato Brachytherapy planning system version
14.3.5, (Elekta AB, Stockholm, Sweden) [15]. The dose
calculation algorithm of the PLATO planning system is
Figure 1 Patient with lower lip T2 SCC during treatment: (A) pre treatment lesion, (B) mold used to distance the lip for external beam
treatment, (C) the interstitial insertions, (D) CMS with embedded catheters, (E + F) the patient during treatment, (G + H) cosmetic and
functional results after 4 years. SCC = Squamous Cell Carcinoma CMS = Customized Mold Sandwich.
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[16]. Target volumes and critical organs, including the
mandible and lip were defined, and the interstitial catheters
as well as the mold catheters were delineated (Figure 2).
The treatment was given in a 2.5-3 Gy fractions BID, to a
total dose of 25–42 Gy.
For evaluation of the catheter-baring mold contribu-
tion, we recalculated the dose with or without the mold,
and compared the DVH of the plans, normalized to
3 Gy fraction.External Beam Radiation Therapy (EBRT)
Patients who had positive cervical lymph nodes or were at
high risk for lymph node metastases, were initially treated
with EBRT. CT simulation was used for treatment
planning- ((Marconi Medical system M8000, Eclipse plan-
ning system (Varian, Palo Alto, California)). Intensity
Modulated Radiation Therapy (IMRT) planning utilizingAnalytical Anisotropic Algorithm (AAA) was used for
treating the neck.Treatment evaluation
To estimate the CMS technique advantages over the
commonly used “classical” interstitial technique, calcula-
tion was done to both techniques –in the same patient.
The dose per fraction was normalized to 3 Gy. The
DVH of the Clinical Tumor Volume (CTV), as well as
dose to the mandible, were calculated. Dose Volume
Histograms for the target volume and the surrounding
normal tissue were generated. To evaluate the contri-
bution of the catheter baring mold, we performed calcu-
lations using the interstitial sleeves only, ignoring the
contribution of the sleeves embedded in the mold. The
dose was reported according to the ICRU 58 guidelines
[17], and the conformal index (COIN) [18] was calcu-
lated for each patient in both plans.
Figure 2 Comparison between the "sandwich" technique and
"classic" interstitial only technique. Reconstructive image of the
interstitial and mold catheters in relation to the lip and the
mandible (A). Comparison of the DVH between the interstitial
catheters only (B) and the CMS (C) techniques at the same level.
Note the invagination of the dose to the mandible in the “classic”
interstitial catheters technique. Coverage by the lip catheters (D,F)
compared to the CMS (E,G) from two different angles. The DVH of
the target in the interstitial catheters only (H) and the CMS (I)
techniques. Note that the high dose regions without the mold are
more than twice that as with the mold. DVH = Dose Volume
Histogram CMS = Customized Mold Sandwich.
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For statistics we used the Paired-Samples T test.
P < 0.05 was considered statistically significant.
Results
Patients
We identified seven patients who were treated with lip
brachytherapy during the study period. All patients were
male; the average age was 58 years (range 36–81). Ac-
cording to TNM staging, all patients had T2 lesions,
ranging from 2 to 3 cm in size. All patients suffered
from squamous cell carcinoma of the lip, six of them in
the lower lip and one in the upper lip. Most of thepatients had a well-differentiated histology, one patient
had moderately to well-differentiated carcinoma, and
one patient had a poorly-differentiated cancer.
All patients received radiation therapy as definitive
treatment; one patient underwent surgical resection ini-
tially, and received brachytherapy alone for recurrent dis-
ease. Patient characteristics are summarized in Table 1.
Patients with positive or clinically suspicious neck
nodes received external beam radiation to the neck as
well. The median follow-up was 47 months (range: 41–
59 months). Cosmetic and functional outcomes were ex-
tracted from doctor follow-up notes.
The Customized Mold Sandwich (CMS) technique
comparing to “classical” interstitial technique
Calculations based on ICRU 58 guidelines [17] showed
treated Volume was in average 8.77cc for the CMS tech-
nique and 8.55cc for the “classical” interstitial only plan.
The coverage of the CTV was 93% vs. 90% for the CMS
over the “classical” interstitial technique respectively
(P < 0.0004). The treated volume is the tissue volume
that, based on the actual implant, receives at least 3Gy
per fraction. The high-dose region is the volume encom-
pass by isodose corresponding to 150% of the prescribed
dose (V150). We found a statistically significant improve-
ment of 20% (range 1-47%) in the high dose region
Table 2 The plan characteristic reported according to ICRU 58
“sandwich” technique “Classic” interstitial
Volume (cc) % Volume (cc) %
Patient 1 Treated Volume 7.39 95.48% 7.29 94.19%
CTV-7.74cc High-dose region 4.53 58.53% 5.91 76.36%
Low-dose region 0.08 1.03% 0.25 3.23%
Patient 2 Treated Volume 6.49 92.71% 6.37 91.00%
CTV-7.00cc High-dose region 3.7 52.86% 4.17 59.57%
Low-dose region 0.33 4.71% 0.29 4.14%
Patient 3 Treated Volume 2.43 92.40% 2.35 89.35%
CTV-2.63cc High-dose region 1.55 58.94% 1.57 59.70%
Low-dose region 0.07 2.66% 0.11 4.18%
Patient 4 Treated Volume 8.75 97.01% 8.56 94.90%
CTV-9.02cc High-dose region 4.92 54.55% 5.6 62.08%
Low-dose region 0.11 1.22% 0.2 2.22%
Patient 5 Treated Volume 9.88 88.53% 9.63 86.29%
CTV-11.16cc High-dose region 5.92 53.05% 7.01 62.81%
Low-dose region 0.78 6.99% 1.15 10.30%
Patient 6 Treated Volume 8.64 93.81% 8.28 89.90%
CTV-9.21cc High-dose region 4.96 53.85% 5.79 62.87%
Low-dose region 0.2 2.17% 0.48 5.21%
Patient 7 Treated Volume 17.81 89.01% 17.36 86.76%
CTV-20.01cc High-dose region 6.31 31.53% 9.3 46.48%
Low-dose region 1.41 7.05% 1.19 5.95%
Calculation of the coverage of the target using the ICRU 58 guidelines for the “sandwich” technique and interstitial catheter only ("classic") for each individual patient.
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gion receiving 90% or less of the prescribed dose im-
proved by 73% in favor of the CMS technique, however
this was not statistically significant. A detailed individual
dosimetry is shown in Table 2.
When we calculated the dose to the maxilla or the
mandible, the dose was negligible in all calculations due
to the physical characteristics of the mold in distancing
the lip. The Conformal Index (COIN) was calculated for
all patients in both techniques and is shown in Table 3.
An improvement of the index from an average of 0.88 toTable 3 The Conformal Index (COIN)
“sandwich” technique Interstitial catheter only
Patient 1 0.930 0.784
Patient 2 0.927 0.910
Patient 3 0.924 0.894
Patient 4 0.970 0.949
Patient 5 0.885 0.863
Patient 6 0.938 0.887
Patient 7 0.884 0.868
Calculation of the Conformal index (COIN) for the “sandwich” technique and
interstitial catheter only for each individual patient.average of 0.92 (p = 0.043) was achieved by using the
CMS technique.
Treatment toxicity
All patients developed a transitory mucositis and lip
edema, which resolved within one month after the end
of treatment. One patient developed a lip infection
shortly after the end of treatment, and was treated with
a one week course of antibiotics, and had an uneventful
recovery.
Long term side effects were minimal and were limited
to minimal fibrosis and dry lips. Skin defects were more
likely to be the result of tumor resolution than radiation
induced. No chronic ulceration or mandibular osteo-
necrosis were noted.
Excellent esthetic and functional results were obtained
in all patients, including a smooth lip contour, effortless
mouth opening, and clear speech. These outcome eva-
luations are based on both follow-up notes and patient
judgment. See Table 4.
Discussion
The CMS technique, which combines interstitial catheters
with a saddle-shaped mold with embedded catheters,
Table 4 Dose, technique and outcomes
Patient Tumor site T stage Previous treatments DoseEBRT to lip
(not inc. neck dose)
Brachytherapy
dose









1. Lower lip T2 none 50 Gy 2 Gy/fr 30 Gy 2 Gy BID 2 2 47 mo 5 5
2. Upper lip T2 none 50 Gy 2 Gy/fr 30 Gy 3 Gy BID 3 4 37 mo 5 5
3. Lower lip T2 none none 42 Gy 3 Gy BID 1 2 32 mo 5 5
4. Lower lip T2 none 50 Gy 2 Gy/fr 18 Gy 3 Gy BID 2 3 33 mo 5 5
5. Lower lip T2 Surgery, close margins 44 Gy 2 Gy/fr 25 Gy 2.5 Gy BID 2 2 29 mo 5 5
6. Lower lip T2 none none 42 Gy 3 Gy BID 4 3 38 mo 5 5
7. Lower lip recurrence T2 post op Wedge resection none 39 Gy 3 Gy BID 2 1 29 mo 5 5
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pared to the “classical” interstitial technique. The addition
of the mold enabled relative sparing of the mandible/
maxilla and adjacent normal tissues by reserving the
region of treatment (i.e. lip) from the bone. Since we disre-
gard the catheters in the mold during the calculation of
the “classical” solution, but not the mold itself with its ad-
vantages, additional benefit was not reflected in the com-
parison of the mandible dose calculations. Our technique
resulted in excellent tumor control rates with minimal
short and long-term toxicity.
Finestres et al. [13] reported on their experience with
28 patients treated with HDR brachytherapy by means
of acrylic applicators without interstitial catheter in-
sertions. All patients had complete remission of their
tumor; excellent cosmetic results were reported, with no
late complications. Guinot et al. [11] reported treatment
for patient with T1-T4 lesions using parallel needles
only, with a template forming a triangular distribution.
They reported a local control rate of 90%. In our study,
we report a technique that combines the advantages of
both methods, a combination of interstitial catheters and
a surface mold. This enabled improving the CTV cover-
age and dose homogeneity, without the need to increase
the number of interstitial sleeves. This may contribute to
the excellent long term outcome in terms of tumor con-
trol cosmetics and functionality.
Weak points in our study include it being retrospec-
tive, and consequently the need to use the same plan-
ning CT for comparison calculations. Therefore, the lip
is pushed away from the mandible by the mold, not only
for the calculation of the CMS technique, but also for
the calculation of the “classic” technique, thus under-
score the advantage that the mold achieves.
Conclusion
Compared to the “classical” interstitial only technique, the
“sandwich” technique of interstitial brachytherapy with a
dedicated mold, achieves better dose volume distribution,
better treatment homogenously and better normal tissue
protection.
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